Matches in DBpedia 2016-04 for { ?s ?p "Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.The oral form of treprostinil was undergoing clinical trials."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Treprostinil abstract "Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.The oral form of treprostinil was undergoing clinical trials.".
- Q3495231 abstract "Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.The oral form of treprostinil was undergoing clinical trials.".
- Treprostinil comment "Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.The oral form of treprostinil was undergoing clinical trials.".
- Q3495231 comment "Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.The oral form of treprostinil was undergoing clinical trials.".